PSMB8
PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.
Overview
The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.00, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.
- 1 · What it is
PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.
- 2 · What goes wrong in cancer
The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH.
- 3 · How drugs use it
No product in this corpus aims at PSMB8 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9545 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P28062 (protein name, function text, keywords and locations (REST API)); CIViC gene PSMB8 (1 evidence items, 0 assertions, 1 variants; diseases: Gastric Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000204264 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.62, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Biology
The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Involved in the generation of spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein. Acts as a major component of interferon gamma-induced sensitivity. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.32 (HGNC).
- Multiple myeloma: Open Targets association 0.62 with plasma cell myeloma (MONDO_0009693)
- Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease
- Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)
- Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PSMB8" OR ABSTRACT:"PSMB8" OR TITLE:"proteasome 20S subunit beta 8" OR ABSTRACT:"proteasome 20S subunit beta 8" OR TITLE:"Proteasome subunit beta type-8" OR ABSTRACT:"Proteasome subunit beta type-8" OR TITLE:"RING10" OR ABSTRACT:"RING10" OR TITLE:"D6S216E" OR ABSTRACT:"D6S216E" OR TITLE:"PSMB5i" OR ABSTRACT:"PSMB5i") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMB8, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetADRM1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA1
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA2
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA3
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA4
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA5
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA6
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.
- TargetPSMA7
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Multiple myeloma, Open Targets Platform.